Constellium SE
Market Movers (8-K)
NYSE
CSTM
Constellium SEConstellium SE announced robust second quarter and first half 2026 financial results, including a record quarterly Segment Adjusted EBITDA, and raised its full-year guidance.
Better than expected
NYSE
CSTM
Constellium SEConstellium SE's Annual General Meeting saw the approval of new and re-appointed directors, alongside a shareholder decision to hold executive compensation votes annually.
NYSE
CSTM
Constellium SEConstellium SE announced robust first quarter 2026 financial results, including record segment Adjusted EBITDA, and has raised its full-year guidance.
Better than expected
NYSE
CSTM
Constellium SEConstellium SE's Board of Directors approved a new share repurchase program of up to $300 million, effective after its 2026 Annual General Meeting.
Better than expected
NYSE
CSTM
Constellium SEConstellium SE reported robust third-quarter 2025 financial results, driven by increased shipments and revenue, leading to a significant raise in its full-year guidance.
Better than expected
NYSE
CSTM
Constellium SEConstellium SE announced Ingrid Joerg will succeed Jean-Marc Germain as Chief Executive Officer, effective January 1, 2026, following a planned leadership succession.
Quarterly Earnings (10-Q)
NYSE
CSTM
Constellium SEConstellium SE announced robust financial results for the second quarter of 2026, driven by increased revenue, improved segment EBITDA, and strategic operational focus.
Better than expected
NYSE
CSTM
Constellium SEConstellium SE announced a significant increase in Q1 2026 revenue and net income, driven by strong performance across its segments and favorable market dynamics.
Better than expected
NYSE
CSTM
Constellium SEConstellium SE reported a significant increase in Q3 2025 net income and revenue, driven by higher shipments and improved operational performance across key segments.
Better than expected
NYSE
CSTM
Constellium SEConstellium SE reported a 9% revenue increase for Q2 2025, reaching $2.103 billion, but net income declined significantly by 53% to $36 million, impacted by higher costs and an increased French surtax.
Worse than expected
NYSE
CSTM
Constellium SEConstellium SE's Q1 2025 results show a revenue increase driven by higher prices, despite volume declines in some segments and lingering impacts from a prior flood.
Worse than expected
Annual Reports (10-K)
NYSE
CSTM
Constellium SEConstellium SE reported a significant increase in net income and revenue for 2025, driven by higher shipments and metal prices, despite ongoing macroeconomic uncertainties.
Better than expected
NYSE
CSTM
Constellium SEConstellium SE files an amendment to its 2024 Annual Report on Form 10-K, updating information on executive compensation, security ownership, and the equity incentive plan.
Worse than expected
NYSE
CSTM
Constellium SEConstellium SE releases its 2024 financial results, highlighting a challenging year with demand weakness and operational disruptions, while voluntarily transitioning to SEC reporting standards.
Worse than expected
Insider Trading (Form 4)
NYSE
CSTM
Constellium SEJean-Christophe Deslarzes, a Director of Constellium Se, purchased 1,490 shares of common stock on August 3, 2026 for $27.24 per share.
NYSE
CSTM
Constellium SEIngrid Joerg, CEO and a Director of Constellium Se, reported a transaction in 2,984 shares of common stock on July 10, 2026.
NYSE
CSTM
Constellium SEDirector John Ormerod reported a transaction involving Constellium SE ordinary shares on June 4, 2026.
NYSE
CSTM
Constellium SEConstellium SE reports a Form 4 filing detailing a transaction by officer Marcus Becker involving the sale of ordinary shares.
NYSE
CSTM
Constellium SEConstellium SE Director Bradley Lee Soultz reported the acquisition of 2,500 ordinary shares.
NYSE
CSTM
Constellium SEConstellium SE reports that SVP Chief Innovation Officer Martin Jarrett sold 4,716 ordinary shares on May 14, 2026.
Proxy Statements (Def-14A)
NYSE
CSTM
Constellium SEConstellium SE is soliciting proxies for its 2026 Annual General Meeting of Shareholders on May 21, 2026, to vote on director appointments, executive compensation, financial statements, and share repurchase authorizations.
Schedule 13D - Activist Investments
NYSE
CSTM
Constellium SEBpifrance Participations sold 4.19 million shares of Constellium SE in block trades, reducing its beneficial ownership to 6.2%.
Schedule 13G - Passive Investments
NYSE
CSTM
Constellium SEFMR LLC, through its subsidiaries and affiliates, has reported beneficial ownership of 5.1% of Constellium SE's ordinary shares as of March 31, 2026.
NYSE
CSTM
Constellium SEMillennium Management LLC and Israel A. Englander have reported a reduced beneficial ownership in Constellium SE, now holding 2.5% of the company's ordinary shares.
NYSE
CSTM
Constellium SEFMR LLC and Abigail P. Johnson have disclosed a 7.7% beneficial ownership in Constellium SE, holding over 10.5 million ordinary shares as of December 31, 2025.
NYSE
CSTM
Constellium SEMillennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, has reported a passive 5.3% beneficial ownership stake in Constellium SE.
NYSE
CSTM
Constellium SET. Rowe Price Investment Management, Inc. has reported a reduction in its beneficial ownership of Constellium SE common stock to 4.5%.
Worse than expected
NYSE
CSTM
Constellium SESCHEDULE 13G/A: T. Rowe Price Boosts Constellium SE Stake to 10%
T. Rowe Price Investment Management, Inc. has reported a 10.0% beneficial ownership stake in Constellium SE, totaling over 14.3 million shares.